Listen Top Shows Blog

The biosimilars challenge to Humira revs up

The biosimilars challenge to Humira revs up

Update: 2023-07-20

Share

Description

Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Healing the health divide for women

Healing the health divide for women

2024-11-2220:54

Modifi gets creative on the rocky road to a multibillion-dollar buyout

Modifi gets creative on the rocky road to a multibillion-dollar buyout

2024-11-1323:56

A quantum leap into the future of drug development

A quantum leap into the future of drug development

2024-10-1717:32

Gene and cell therapies will propel innovation, says Astellas CCO

Gene and cell therapies will propel innovation, says Astellas CCO

2024-10-0727:17

Capricor’s CEO pursues a BLA and talks rare disease

Capricor’s CEO pursues a BLA and talks rare disease

2024-09-2715:50

The first half of 2024 was strong as M&As and financings dominate

The first half of 2024 was strong as M&As and financings dominate

2024-07-2618:01

The cost of delays in development and sales: It’s probably not what you think

The cost of delays in development and sales: It’s probably not what you think

2024-07-1716:44

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference

2024-05-3013:11

Fibrobiologics walks the unconventional financing path

Fibrobiologics walks the unconventional financing path

2024-05-1518:16

Back to fundamentals: The latest numbers point to better times

Back to fundamentals: The latest numbers point to better times

2024-05-0621:38

Mark McKenna storms back with Mirador and eyes the development landscape

Mark McKenna storms back with Mirador and eyes the development landscape

2024-04-2325:01

Biopharma execs seek to avoid pain points in AI integration

Biopharma execs seek to avoid pain points in AI integration

2024-04-1619:19

Six biopharma executives consider a tough 2023 and are hopeful for a better 2024

Six biopharma executives consider a tough 2023 and are hopeful for a better 2024

2023-12-1117:05

AI: driving drug development from effective to remarkable

AI: driving drug development from effective to remarkable

2023-09-0626:32

The struggle is real: The first half of 2023 was an uphill climb

The struggle is real: The first half of 2023 was an uphill climb

2023-08-1625:47

The biosimilars challenge to Humira revs up

The biosimilars challenge to Humira revs up

2023-07-2017:06

Preventing opioid overdoses with a smart patch

Preventing opioid overdoses with a smart patch

2023-06-0523:20

Better times ahead for the biopharma sector? Could be, the new numbers say

Better times ahead for the biopharma sector? Could be, the new numbers say

2023-04-2428:02

Radiopharmaceuticals: The next big disrupter?

Radiopharmaceuticals: The next big disrupter?

2023-04-0513:58

Cambrian carves out a new niche as it works to keep people from getting sick

Cambrian carves out a new niche as it works to keep people from getting sick

2023-02-2128:06

00:00

00:00

x

The biosimilars challenge to Humira revs up

The biosimilars challenge to Humira revs up